|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.58 USD | -4.24% |
|
-1.86% | -14.13% |
| 05-21 | Biodesix, Inc. to Present New Data on the Nodify XL2 Test at ATS 2024 Annual Meeting | CI |
| 05-13 | TD Cowen Starts Biodesix With Buy Rating, $2.80 Price Target | MT |
Biodesix, Inc. reaffirmed revenue guidance for the full year 2024. for the year, the company expects total revenue of $65 million and $68 million.
| 1st Jan change | Capi. | |
|---|---|---|
| -14.13% | 229M | |
| -18.42% | 8.53B | |
| +65.89% | 4.26B | |
| +6.22% | 2.71B | |
| -1.93% | 2.63B | |
| -57.14% | 1.72B | |
| -19.16% | 1.67B | |
| -20.01% | 1.45B | |
| +15.38% | 1.19B | |
| -50.40% | 1.01B |
BIODESIX, INC. 
